-
Significant Improvement in PFS and DOR: LITESPARK-011 Validates Clinical Benefit of a Novel Combination Following Immunotherapy Progression
For patients with advanced renal cell carcinoma (RCC) who have progressed after anti-PD-(L)1 therapy, a consensus standard of care is currently lacking. Belzutifan, a first-in-class HIF-2α inhibitor, combined with the VEGFR-TKI lenvatinib, has emerged as a promising therapeutic strategy. At a recent academic conference, Professor Robert J. Motzer from Memorial Sloan Kettering Cancer Center (MSKCC)…
-
Toward Precision Bladder Preservation: RETAIN 2 Validates Nivolumab Plus NAC Potential; ctDNA Emerges as a Key Systemic Risk Predictor
At the recent genitourinary oncology symposium, Dr. Pooja Ghatalia from Fox Chase Cancer Center presented the primary clinical outcomes of the RETAIN 2 trial. She also provided an integrated analysis of the RETAIN 1 and RETAIN 2 trials, focusing on the role of circulating tumor DNA (ctDNA) in guiding response-adapted bladder preservation for patients with…
-
Dual Liquid Biopsy Insights: Combining utDNA and ctDNA to Identify pCR and Inform Bladder-Sparing Strategies in MIBC
At the recent ASCO Annual Meeting, Professor Michiel S. van der Heijden from the Netherlands Cancer Institute (NKI) presented the latest biomarker analysis from the Phase III NIAGARA trial. The study investigated the dynamics of urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) receiving perioperative durvalumab in…
-
Milestone Breakthrough: KEYNOTE-B15 Study Confirms Perioperative EV plus Pembrolizumab Significantly Improves Outcomes in Cisplatin-Eligible MIBC
During a recent clinical oncology symposium, Professor Matthew D. Galsky from the Icahn School of Medicine at Mount Sinai presented the primary results of the Phase 3 KEYNOTE-B15 study (also known as EV-304). This trial evaluated the efficacy and safety of perioperative enfortumab vedotin (EV) in combination with pembrolizumab for patients with cisplatin-eligible muscle-invasive bladder…
-
A Breakthrough in Luminal-Targeted Therapy: First-in-Class PPARG Inhibitor FX-909 Demonstrates Potent Antitumor Activity and Precision Subtyping Potential
At a recent major international oncology conference, Dr. Matthew D. Galsky from Mount Sinai presented updated data from a Phase 1 clinical trial (Late-Breaking Abstract, LBA639) and associated biomarker analysis of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients with advanced urothelial carcinoma (UC). The study data were simultaneously published in the…
-
HCRN GU 20-444 Trial: Phase II Clinical Results of Pembrolizumab Monotherapy with a Response-Guided Bladder-Sparing Strategy in MIBC
While radical cystectomy (RC) remains the standard of care for muscle-invasive bladder cancer (MIBC), it is associated with significant morbidity and long-term quality-of-life impacts. For elderly patients and those ineligible for cisplatin-based chemotherapy, effective bladder-sparing strategies are urgently needed in clinical practice. At a recent major international oncology conference, Dr. Jonathan F. Anker from Mount…
-
Toward Molecular Remission: IMvigor011 Exploratory Analysis Confirms ctDNA Concentration and Dynamics as Precise Prognostic Indicators in MIBC
At a recent academic conference, Professor Joaquim Bellmunt from the Dana-Farber Cancer Institute, Harvard Medical School, presented the latest exploratory analysis results from the IMvigor011 trial. He provided an in-depth interpretation of the prognostic and predictive value of circulating tumor DNA (ctDNA) dynamics during adjuvant atezolizumab treatment for muscle-invasive bladder cancer (MIBC) following surgery.
-
43.2% Clinical Benefit Rate: Cabozantinib Demonstrates Potential in Heavily Pretreated R/R GCT
During a recent oncology symposium, Dr. Jennifer King from Indiana University presented the results of a Phase II clinical trial (Abstract 587) evaluating cabozantinib in patients with relapsed/refractory germ-cell tumors (R/R GCT). This study explores the efficacy and safety of a multi-target tyrosine kinase inhibitor (TKI) in a patient population that has failed multiple lines…
Connecting Medical Expertise through Media